High NCAPG2 expression is associated with advanced clinical tumor stage and reduced survival time in patients with lung adenocarcinoma [60], and PTTG1 has been correlated with non-small cell lung cancer progression and is an independent poor prognostic factor in patients with non-small cell lung cancer [61]. Here, NCAPG2 is linked to lung adenocarcinoma.